Maze Therapeutics, INC Form 4 insider transactions

Catherine A. Sohn, a director at Maze Therapeutics, Inc., executed pre-planned sales of common stock totaling 29,413 shares following option exercises.

Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised stock options and subsequently sold shares totaling 4,844 units in early January 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed pre-planned option exercises and subsequent sales of common stock, realizing significant gains.

Maze Therapeutics' Chief Strategy and Business Officer, Atul Dandekar, exercised stock options and subsequently sold a significant portion of common stock under a pre-arranged 10b5-1 trading plan.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options and sold 45,000 shares for approximately $1.8 million under a pre-arranged trading plan.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised stock options and subsequently sold an equal number of shares totaling 15,000, as part of a pre-arranged 10b5-1 trading plan.

Maze Therapeutics Director Charles J. Homcy received 1,489 shares of common stock through a pro rata distribution from Third Rock Ventures affiliates.

Third Rock Ventures IV, L.P. distributed 1.6 million shares of Maze Therapeutics common stock to its partners for no consideration.

Maze Therapeutics Director Charles J. Homcy reported gifting 28,423 shares of common stock, reducing his direct beneficial ownership.

Herve Hoppenot, a Director at Maze Therapeutics, Inc., was granted 36,000 stock options with an exercise price of $27.52.

Maze Therapeutics, Inc. granted 22,000 restricted stock units to its General Counsel and Corporate Secretary, Courtney Phillips, vesting over two years.

Maze Therapeutics, Inc. has granted its Chief Scientific Business Officer, Atul Dandekar, 25,000 restricted stock units, aligning executive incentives with shareholder value.

Maze Therapeutics CEO Jason V Coloma was granted 100,000 Restricted Stock Units, vesting over two years, as disclosed in a recent SEC Form 4 filing.

Maze Therapeutics, Inc. granted 40,000 Restricted Stock Units to Harold Bernstein, President, R&D & CMO, as part of his compensation, vesting over two years.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, Inc., was granted 22,000 Restricted Stock Units, vesting over two years.

Maze Therapeutics Director Daniel K. Spiegelman received a grant of 18,000 stock options with an exercise price of $23.67, vesting monthly over nine months.

Catherine A. Sohn, a Director at Maze Therapeutics, acquired 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics director Richard H. Scheller was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics director Jonathan E. Lim was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Sekar Kathiresan, a Director at Maze Therapeutics, Inc., was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics Director Charles J. Homcy was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics Director Neil Exter acquired 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Nancy C Andrews, a Director at Maze Therapeutics, Inc., was granted 18,000 stock options with an exercise price of $23.67, vesting monthly over nine months starting October 1, 2025.

Maze Therapeutics Director Richard H. Scheller sold all 20,744 shares of common stock for approximately $22.37 per share in a pre-planned transaction.

Maze Therapeutics' Chief Financial Officer, Tahir Misbah, was granted 325,000 stock options with an exercise price of $15.32.

Maze Therapeutics Director Neil Exter was granted 16,000 stock options with an exercise price of $13.35, vesting monthly over 16 months.

Third Rock Ventures files Form 4 detailing the conversion of preferred stock to common stock and changes in beneficial ownership following Maze Therapeutics' initial public offering.

Director Jonathan E. Lim reports changes in beneficial ownership of Maze Therapeutics stock following the conversion of preferred stock and option transactions.

Director Charles J. Homcy reports changes in beneficial ownership of Maze Therapeutics stock and derivative securities following the company's IPO and related conversions.